Page 33 - Andreaf Wainer News Today

Metis Global Partners LLC boosted its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 20.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,139 shares of the healthcare product maker’s stock after acquiring an additional 12,199 shares during the […]

Van Cleef Asset Management Inc lessened its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 11.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,000 shares of the healthcare product maker’s stock after selling 764 shares during the […]

Abbott Laboratories (NYSE:ABT – Get Free Report) had its price target hoisted by equities research analysts at Citigroup from $123.00 to $126.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the healthcare product maker’s stock. Citigroup’s price objective would suggest a potential upside of […]

Abbott Laboratories (NYSE:ABT – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Thursday, Marketbeat reports. They presently have a $128.00 price target on the healthcare product maker’s stock. Royal Bank of Canada’s price target would suggest […]

Global Wealth Management Investment Advisory Inc. raised its position in Abbott Laboratories (NYSE:ABT – Free Report) by 25.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,076 shares of the healthcare product maker’s stock after purchasing an additional 215 shares during the quarter. […]

Abbott Laboratories (NYSE:ABT – Get Free Report) had its price objective increased by analysts at Citigroup from $123.00 to $126.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the healthcare product maker’s stock. Citigroup’s price target suggests a potential upside of 12.49% from the company’s previous […]

Callan Capital LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 33.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,104 shares of the healthcare product maker’s stock after buying an additional 1,018 shares […]

Vestmark Advisory Solutions Inc. reduced its position in Abbott Laboratories (NYSE:ABT – Free Report) by 76.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 20,529 shares of the healthcare product maker’s stock after selling 66,354 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Abbott Laboratories […]

Washington Trust Bank lifted its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 80.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,619 shares of the healthcare product maker’s stock after acquiring an additional 11,448 shares […]

Vestmark Advisory Solutions Inc. lessened its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 76.4% in the 3rd quarter, Holdings Channel reports. The firm owned 20,529 shares of the healthcare product maker’s stock after selling 66,354 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Abbott Laboratories were worth $1,988,000 as of its […]